Find out how to tackle one of the biggest challenges in treating cancer with Genomic testing for cancer treatment Read more

EndoPredict Breast Cancer Prognostic Test

 

Prof. Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Head of Breast Interdisciplinary Cancer Center Department of Obstetrics and Gynecology, HELIOS Clinic Berlin-Buch in Berlin, Germany

Watch Prof. Untch’s case study

  • 43 years old, premenopausal, pT1c, N0, G2, L0, V0, R0, ER 100%, HER2-, PR 100%, Ki67 15%, early-stage breast cancer patient
  • Poll of other clinicians’ case opinions
  • How her EndoPredict result supported a confident treatment decision
  • Clinical validation of the test in this patient group

Get more case studies

Get in touch

Clear results

Informed conversations

Confident decisions

Get clear results

     Based on her individualized risk score. See her full report

8%

risk of distant recurrence within 10 years

2%

absolute individualized chemotherapy benefit

6%

5–15 year late distant recurrence risk*
*with 5 years of endocrine therapy alone

Have informed conversations

   Simple to interpret, straightforward to explain. For example:

“Your EndoPredict result shows that your cancer is at low risk of recurrence”

“The EndoPredict score is based on the gene activity in your cancer and its risk profile”

“There is a 92% probability your cancer will not recur
within 10 years”

“Chemotherapy reduces this risk of recurrence by 2%, but this small benefit may not outweigh the potential for side effects”

Make confident decisions

   Knowing her result
  • Is from the most accurate prognostic and predictive second generation test1,2

    •  

  • Combines her clinical factors with a molecular gene expression score, based on genes associated with early and late recurrence3-5
  • Is clinically validated and prospectively confirmed2-10

 

  • Includes her 15 year distant recurrence risk, providing the longest prognostic period compared to other genomic signatures4

What it means for this patient

Based on her clear result, this patient and her clinician decided to proceed without chemotherapy, allowing her to avoid the potential side effects of toxic treatments with confidence in her low long-term recurrence risk.

Her report breakdown

    Other case studies

    Sign up to receive more case studies and discover how EndoPredict guides chemotherapy decisions
    in other clinical scenarios. Includes access to the full webinar, with Q&A and prospective data.

    References

    1. Sestak, Ivana et al. “Comparison Of The Performance of 6 Prognostic Signatures For Estrogen Receptor-Positive Breast Cancer.” JAMA Oncology, vol 4, no. 4, 2018, pp. 545–553
    2. Sestak, Ivana et al. “Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.” Breast Cancer Research and Treatment, vol. 176, 2019, pp. 377–386.
    3. Filipits, Martin et al. “Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.” Clinical Cancer Research, vol. 25, no. 13, 2019, pp. 3865–3872.
    4. Filipits, Martin et al. “A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors.” Clinical Cancer Research, vol. 17, no. 18, 2011, pp. 6012–6020.
    5. Dubsky, Peter et al. “The EndoPredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients.” British Journal Of Cancer, vol. 109, no. 12, 2013, pp. 2959–2964.
    6. Buus, Richard et al. “Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.” Journal of the National Cancer Institute, vol. 108, no. 11, 2016, p.149.
    7. Martín, Miguel et al. “Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.” Journal of Clinical Oncology, vol. 20, 2002, pp. 2593–2599.
    8. Constantinidou, Anastasia et al. “Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.” Clinical Cancer Research, vol. 28, no. 20, 2022, pp. 4435–4443.
    9. Simon, Richard et al. “Use Of Archived Specimens In Evaluation Of Prognostic And Predictive Biomarkers.” Journal Of The National Cancer Institute, vol 101, n. 21, 2009, pp. 1446–1452
    10. Penault-Llorca, Frederique et al. “Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of *** (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)“. SABCS 2021, PD-09-08 Spotlight Poster Discussion 9